Ultrasound Pacing: A New Dawn for Heart Failure Treatment

SUNNYVALE, CA – April 09, 2026 – As the world’s leading cardiologists and electrophysiologists prepare to gather in Chicago for the Heart Rhythm 2026 conference, one company is poised to capture the spotlight with a technology that fundamentally rethinks a cornerstone of heart failure treatment. EBR Systems, Inc. will arrive with significant momentum, showcasing its WiSE® System—the world’s first and only leadless pacing system designed to stimulate the heart’s left ventricle from within.

Following a landmark FDA approval in 2025 and the successful start of its U.S. commercial launch, the company's strong presence at the conference signals a pivotal moment. It marks a transition from clinical trial success to real-world application for a device that offers hope to a large, underserved segment of heart failure patients for whom traditional therapies have failed or were never an option.

Beyond the Wires: A Technological Leap for CRT

For decades, Cardiac Resynchronization Therapy (CRT) has been a lifeline for many patients with heart failure, using electrical leads to coordinate the pumping action of the heart’s ventricles. However, the Achilles' heel of this therapy has always been the LV lead—a thin, insulated wire threaded through the coronary sinus veins on the heart's surface. These leads are associated with a significant number of complications, including fractures, dislodgement, infections, and venous blockages. Furthermore, for a substantial portion of patients—estimated at up to 40% of those eligible—challenging cardiac anatomy makes placing the LV lead difficult or impossible.

EBR Systems' WiSE (Wireless Stimulation Endocardially) System sidesteps these issues entirely. Instead of a wire, it uses a novel, ultrasound-based approach. The system consists of two main components: a small transmitter and battery surgically placed under the skin, and a tiny, rice-sized electrode implanted directly on the inner wall of the left ventricle (the endocardium). The transmitter detects the pacing pulse from a co-implanted pacemaker or defibrillator and, within milliseconds, sends a targeted ultrasound wave to the electrode. The electrode converts this acoustic energy into an electrical pulse, stimulating the heart muscle in perfect synchrony.

This leadless, endocardial approach is a paradigm shift. It not only eliminates the primary source of complications in traditional CRT but also allows physicians to place the electrode at the precise, optimal location inside the left ventricle, unconstrained by the patient's venous anatomy. This enables a more physiological and potentially more effective resynchronization, offering a crucial new option for patients who have exhausted other possibilities.

From Landmark Trial to Real-World Validation

The technology's promise is backed by robust clinical evidence. The foundation of its FDA approval was the SOLVE-CRT pivotal trial, which was stopped early in 2023 for meeting its pre-specified criteria for success. The results, published in the peer-reviewed JAMA Cardiology, were compelling. The trial's primary efficacy endpoint showed a 16.4% average reduction in left ventricular end-systolic volume—a key indicator of improved heart function—far exceeding the performance goal of 9.3%. On the safety front, the trial demonstrated an 80.9% freedom from device- and procedure-related complications at six months, surpassing the 70% goal.

“Our presence at Heart Rhythm 2026 comes at a pivotal time for EBR," said John McCutcheon, President and CEO of EBR Systems, in a recent statement. "This year’s Heart Rhythm conference is an exciting opportunity to demonstrate how EBR is advancing cardiac resynchronization therapy to deliver better results to patients.”

Building on this success, EBR is now gathering long-term, real-world data through the WiSE-UP post-approval study. The observational study, which began enrolling patients in late 2025, will follow more than 300 individuals across 50 U.S. centers for five years. This will provide invaluable insights into the system's performance in a broader patient population. At the upcoming conference, Dr. Niraj Varma of the Cleveland Clinic is scheduled to present the first look at this data in a talk titled, “Real World Experience with the WiSE System: Early Post-Approval US Practice and Outcomes,” which is expected to draw significant attention.

Paving the Path to Widespread Adoption

While innovative technology and strong clinical data are essential, market access is paramount. Here, EBR Systems has executed a swift and effective commercialization strategy since its FDA approval in April 2025. The company has not only completed its first commercial implants in the U.S. but has also secured critical reimbursement pathways that are vital for hospital adoption.

The Centers for Medicare & Medicaid Services (CMS) granted the WiSE System both a New Technology Add-On Payment (NTAP) for inpatient procedures and a Transitional Pass-Through (TPT) payment for outpatient settings, both effective in late 2025. The NTAP approval provides hospitals with reimbursement of up to $41,145 per procedure on top of standard payments, mitigating the financial barriers that often slow the adoption of breakthrough devices. This three-year program is designed specifically to encourage the use of new technologies that offer substantial clinical improvement.

This financial framework is a game-changer, giving hospitals the confidence to invest in the training and infrastructure needed to offer the WiSE System. It ensures that cost does not stand in the way of providing this new standard of care to eligible patients.

Redefining the Cardiac Rhythm Management Market

The CRT market has long been dominated by Medtronic, Abbott, and Boston Scientific, all of which offer sophisticated lead-based systems. While these companies have also pioneered leadless technology with right-ventricular pacemakers like the Micra and Aveir, EBR Systems has carved out a unique and protected space. The WiSE System is not a direct competitor to these RV pacemakers; it is a complementary technology that solves a different problem—leadless left ventricular pacing for CRT.

EBR estimates its initial addressable market at $2.5 billion, focusing on the high-risk and previously untreatable patient populations. “This isn't an incremental improvement; it's a fundamental shift in how we approach resynchronization for a large, underserved patient group,” noted one leading electrophysiologist involved in early studies. By providing a solution where none existed, the company is expanding the entire CRT market rather than just competing for existing share.

The symposiums and data presentations at Heart Rhythm 2026 will serve as a major platform for EBR to educate the clinical community on this new treatment modality. As physicians gain more experience and long-term data from the WiSE-UP study accumulates, this ultrasound-powered system may well become an indispensable tool in the fight against heart failure.